Immunotherapy
News and reporting on cancer immunotherapy.
Immatics Prices $150M Stock Offering
The firm plans to use the proceeds to advance its pipeline of T-cell receptor therapies and support their manufacturing, production, and commercialization.
The firm is gearing up for a registration-directed trial based on a positive Phase Ib readout and after discussions with US and German health authorities.
Gritstone Files for Chapter 11 Bankruptcy
The firm will use the court-administered restructuring process to pursue strategic alternatives so it can continue developing vaccines and immunotherapies.
Immatics to Raise $150M in Public Stock Offering
The firm is developing T-cell receptor therapies for advanced solid tumors including metastatic melanoma.
Aurigene Oncology Advancing BCMA-Directed CAR T-Cell Therapy in Multiple Myeloma Trial
After seeing a 100 percent response rate in Phase I, Indian health authorities said the firm can test ribrecabtagene autoleucel in Phase II of the SWASTH trial.